Drugs / NK-104-CR
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02799758 | Feb 2016 → Jul 2017 | hyperlipidemia | Kowa Research Institute, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT02670434 | Jan 2016 → Jul 2017 | hyperlipidemia | Kowa Research Institute, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NK-104-CR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02799758 ↗ |
| Route | Oral | “orally once daily” NCT02799758 ↗ |